209 related articles for article (PubMed ID: 38515567)
1. The prognostic value of absolute lymphocyte count and neutrophil-to-lymphocyte ratio for patients with metastatic breast cancer: a systematic review and meta-analysis.
Sang B; Fan Y; Wang X; Dong L; Gong Y; Zou W; Zhao G; He J
Front Oncol; 2024; 14():1360975. PubMed ID: 38515567
[TBL] [Abstract][Full Text] [Related]
2. Absolute Lymphocyte Count as an Independent Prognostic Factor in Metastatic Breast Cancer: A Retrospective Study.
Sawa A; Bando H; Kamohara R; Takeuchi N; Terasaki A; Okazaki M; Iguchi-Manaka A; Hara H
Oncology; 2022; 100(11):591-601. PubMed ID: 36099888
[TBL] [Abstract][Full Text] [Related]
3. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis.
Ethier JL; Desautels D; Templeton A; Shah PS; Amir E
Breast Cancer Res; 2017 Jan; 19(1):2. PubMed ID: 28057046
[TBL] [Abstract][Full Text] [Related]
4. High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin-but not with treatment of physician's choice-in the EMBRACE study.
Miyoshi Y; Yoshimura Y; Saito K; Muramoto K; Sugawara M; Alexis K; Nomoto K; Nakamura S; Saeki T; Watanabe J; Perez-Garcia JM; Cortes J
Breast Cancer; 2020 Jul; 27(4):706-715. PubMed ID: 32133606
[TBL] [Abstract][Full Text] [Related]
5. Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial.
Tokunaga E; Miyoshi Y; Dozono K; Kawaguchi T; Toi M
Oncologist; 2024 Mar; 29(3):e319-e329. PubMed ID: 37971418
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
Leng J; Wu F; Zhang L
Front Oncol; 2022; 12():734948. PubMed ID: 35651788
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers to prognosticate survival in advanced gastric cancer patients in the era of immunotherapy: a systematic review and meta-analysis.
Matsas S; Aguiar PN; Del Giglio A
J Gastrointest Oncol; 2024 Feb; 15(1):33-51. PubMed ID: 38482212
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
[TBL] [Abstract][Full Text] [Related]
9. Utility of the Absolute Lymphocyte Count and Neutrophil/Lymphocyte Ratio for Predicting Survival in Patients with Metastatic Breast Cancer on Eribulin: A Real-World Observational Study.
Ueno A; Maeda R; Kin T; Ito M; Kawasaki K; Ohtani S
Chemotherapy; 2019; 64(5-6):259-269. PubMed ID: 32305977
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for breast cancer patients: An updated meta-analysis of 17079 individuals.
Guo W; Lu X; Liu Q; Zhang T; Li P; Qiao W; Deng M
Cancer Med; 2019 Aug; 8(9):4135-4148. PubMed ID: 31197958
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
12. A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab.
Hong J; Chen X; Gao W; Zhu S; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Fei X; Lin L; Shen K
Cancer Manag Res; 2019; 11():3371-3379. PubMed ID: 31114373
[No Abstract] [Full Text] [Related]
13. Predictive value of the neutrophil-to-lymphocyte ratio in the prognosis and risk of death for adult sepsis patients: a meta-analysis.
Wu H; Cao T; Ji T; Luo Y; Huang J; Ma K
Front Immunol; 2024; 15():1336456. PubMed ID: 38562922
[TBL] [Abstract][Full Text] [Related]
14. Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer.
Jimbo H; Horimoto Y; Ishizuka Y; Nogami N; Shikanai A; Saito M; Watanabe J
Breast Cancer Res Treat; 2022 Nov; 196(2):291-298. PubMed ID: 36156756
[TBL] [Abstract][Full Text] [Related]
15. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis.
Sacdalan DB; Lucero JA; Sacdalan DL
Onco Targets Ther; 2018; 11():955-965. PubMed ID: 29503570
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of baseline neutrophil/lymphocyte ratio in HER2-positive metastatic breast cancer: exploratory analysis of data from the CLEOPATRA trial.
Ding N; Pang J; Liu X; He X; Zhou W; Xie H; Feng J; Wang G; Tang J; Cao J; He L; He Y; Wang S; Xiao Z
Breast Cancer Res; 2024 Jan; 26(1):9. PubMed ID: 38212845
[TBL] [Abstract][Full Text] [Related]
17. Predictive impact of absolute lymphocyte counts for progression-free survival in human epidermal growth factor receptor 2-positive advanced breast cancer treated with pertuzumab and trastuzumab plus eribulin or nab-paclitaxel.
Araki K; Ito Y; Fukada I; Kobayashi K; Miyagawa Y; Imamura M; Kira A; Takatsuka Y; Egawa C; Suwa H; Ohno S; Miyoshi Y
BMC Cancer; 2018 Oct; 18(1):982. PubMed ID: 30326862
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of a combined fibrinogen and inflammation-based index in patients with metastatic breast cancer.
Liu Q; Fang S; Liang S; Lv J; Wang G; Tang R; Ji X; Zhao T; Li J; Xu L; Ma L; Wang R; Li H
Transl Cancer Res; 2020 Nov; 9(11):7065-7078. PubMed ID: 35117312
[TBL] [Abstract][Full Text] [Related]
19. Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 Inhibitors.
Kanaoka H; Nagahashi M; Atake Y; Hattori A; Bun A; Fukui R; Ozawa H; Fujimoto Y; Higuchi T; Natori K; Imamura M; Murase K; Takatsuka Y; Miyoshi Y
Anticancer Res; 2022 Oct; 42(10):4867-4878. PubMed ID: 36192009
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis.
Su L; Zhang M; Zhang W; Cai C; Hong J
Medicine (Baltimore); 2017 Mar; 96(11):e6364. PubMed ID: 28296774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
